Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
VEGF Trap-Eye 2.0mg
Regeneron UK Limited
Macular Edema Secondary to Central Retinal Vein Occlusion
1 trial -
VERDYE 5 mg/ml poeder voor oplossing voor injectie
Disc Medicine
Histologically confirmed solid malignancy (e.g., head and neck, gastrointestinal, hepatobiliary, breast, genitourinary, sarcoma)
1 trial -
VINCRISTINE SULFATE, RITUXIMAB, RITUXIMAB, APIXABAN, Golcadomide, PREDNISONE, DOXORUBICIN HYDROCHLORIDE, CYCLOPHOSPHAMIDE MONOHYDRATE, Golcadomide, Golcadomide 0.2 mg capsule, Golcadomide 0.3 mg capsule, Golcadomide 0.4 mg capsule, Golcadomide, Neulasta 6 mg solution for injection, PREDNISOLONE , VINCRISTINE SULFATE
Celgene Europe Limited
High-risk Large B-cell Lymphoma
1 trial -
VP4896
Voyager Therapeutics
Alzheimer's Disease
1 trial -
VYDURA 75 mg oral lyophilisate, 35 mg oral lyophilisate, Placebo for 75 mg Rimegepant, Placebo for 50 mg rimegepant, 50 mg oral lyophilisate, Placebo for 35 mg rimegepant, Placebo for 25 mg Rimegepant, 25 mg oral lyophilisate
Pfizer Australia Pty Ltd
Acute Migraine (with or without aura)
1 trial -
Vaxneuvance suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed), Pneumococcal Conjugate Vaccine (PCV)
Sanofi-aventis Healthcare Pty Ltd
Pneumococcal Immunization
1 trial -
Veltassa 8.4 g powder for oral suspension, Placebo
Istituto Gentili S.r.l.
End Stage Kidney Disease on chronic dialysis therapy
1 trial -
Venglustat GZ402671
Sanofi Pasteur
Congenital Cystic Kidney Disease
1 trial -
Ventoclax
Xiyuan Hospital of China Academy of Chinese Medical Sciences
AML (Acute Myelogenous Leukemia)
1 trial -
Vericiguat
Merck KGaA, Darmstadt, Germany
Chronic Heart Failure With Reduced Ejection Fraction
1 trial -
Verzenios 150 mg film-coated tablets, Kisqali 200 mg film-coated tablets, Faslodex 250 mg solution for injection., IBRANCE 75 mg film-coated tablets, LEUPRORELIN , Verzenios 100 mg film-coated tablets, RO7197597, RIBOCICLIB, IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, Verzenios 50 mg film-coated tablets
Hoffmann-La Roche
Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
1 trial -
Vibegron, Vibegron, Vibegron, Vibegron, Vibegron, Vibegron, Vibegron
Lacuna Pharma Pty Ltd
Neurogenic Detrusor Overactivity (NDO)
1 trial -
Vidaza 25 mg/ml powder for suspension for injection, AG-120/S95031 250mg film-coated tablet
The George Institute
Hypomethylating agent (HMA) naive myelodysplastic syndromes Myelodysplastic Symdrome (MDS), Myelodysplastic Symdrome (MDS)
1 trial -
Vidaza 25 mg/ml powder for suspension for injection, AG-120/S95031 250mg film-coated tablet, Placebo to Match AG-120 Tablet, 250 mg, is supplied as a film-coated tablet for oral administration.
The George Institute
Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation
1 trial -
Vidaza 25 mg/ml powder for suspension for injection, Venclyxto 100 mg film-coated tablets
The George Institute
Acute Myeloid Leukemia, ONCOLOGY
1 trial -
Vincristine placebo, VINCRISTINE , Polivy 140 mg powder for concentrate for solution for infusion., MabThera 500 mg concentrate for solution for infusion
Hoffmann-La Roche
Previously Untreated Diffuse large B-cell lymphoma (DLBCL)
1 trial -
Vocabria 600 mg prolonged-release suspension for injection, REKAMBYS 900 mg prolonged-release suspension for injection
ViiV Healthcare Pty Ltd
HIV Infections
1 trial -
Vonoprazan
Phathom Pharmaceuticals
Non-Erosive Gastro-Esophageal Reflux Disease
2 trials -
Vortioxetine
Takeda
Generalized Anxiety Disorder
3 trials -
Vyloy 100 mg powder for concentrate for solution for infusion., OXALIPLATIN, FOLINIC ACID, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE, FLUOROURACIL, KEYTRUDA 25 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion., Vyloy 100 mg powder for concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion., Sodium chloride 0.9% intravenous infusion, ASP8951, CAPECITABINE, KEYTRUDA 25 mg/mL concentrate fo
Astellas Pharma GmbH
Gastroesophageal Junction Adenocarcinoma, Gastric Cancer, Gastric Adenocarcinoma
1 trial -
Vyvgart 1 000 mg solution for injection
argenx
Generalized Myasthenia Gravis
1 trial -
Vyvgart 1 000 mg solution for injection in pre-filled syringe, Placebo PH20 SC
argenx
Ocular Myasthenia Gravis
1 trial -
Vyvgart 1 000 mg solution for injection in pre-filled syringe, Placebo for efgartigimod
argenx
Thyroid Eye Disease (TED)
1 trial -
Vyvgart 20 mg/mL concentrate for solution for infusion
argenx
Generalized Myasthenia Gravis (gMG)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources